Cure My Disease

Don't miss your cure!

 Log in / Sign up

Extra vein ablation tested to keep persistent AFib from returning

NCT ID NCT07819175

Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers test whether adding superior vena cava isolation to standard pulmonary vein isolation helps people with persistent atrial fibrillation. About 340 participants aged 18 to 75 whose AFib has lasted less than a year and who are having their first catheter ablation join the study at hospitals in China. Half receive pulmonary vein isolation alone and half receive pulmonary vein isolation plus superior vena cava isolation, both using pulsed field ablation. The trial tracks who stays free of atrial rhythm problems from three months to twelve months after the procedure, along with safety and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pulsed field ablation, a non-heating catheter technique that uses electrical pulses to disconnect abnormal heart rhythm signals
What this could lead to
If adding superior vena cava isolation helps, it could improve how many people with persistent atrial fibrillation stay free of abnormal heart rhythms after a single catheter procedure.
What could go wrong
The extra ablation step may not improve rhythm control and could add procedure time or rare risks. Results from this trial may not apply to people with longer-lasting AFib or previous heart procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 340 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Persistent atrial fibrillation (AFib) duration \< 1 year; 2. Age 18-75 years; 3. Willing to participate in this study, capable of understanding, and has signed the informed consent form; able to complete postoperative follow-up according to the protocol. Exclusion Criteria: 1. Significant cardiac dysfunction or structural abnormality: LVEF \< 50% or left atrial anteroposterior diameter \> 46 mm; 2. Previous left atrial ablation or cardiac surgery (including left atrial appendage closure); 3. Presence of permanent pacemaker, CRT, implantable cardiac monitor, or any type of ICD; 4. Previous pulmonary vein stent, pulmonary vein stenosis, or superior vena cava stenosis; 5. Previous unilateral phrenic nerve palsy; 6. Any prosthetic heart valve or moderate-to-severe (grade 3-4) valvular regurgitation/stenosis; 7. Any cardiac surgery, myocardial infarction, PCI/PTCA, or coronary stent implantation within 3 months prior to signing informed consent; 8. Unstable angina, NYHA class III/IV heart failure, primary pulmonary hypertension, rheumatic heart disease, or hypertrophic cardiomyopathy; 9. Thrombocytosis/thrombocytopenia, any disease contraindicating long-term anticoagulation, active systemic infection; 10. Atrial fibrillation due to reversible causes (e.g., hyperthyroidism); 11. Stroke or TIA within 6 months prior to signing informed consent; 12. Pregnant or lactating women; 13. Life expectancy \< 1 year; 14. Currently participating in or expected to participate in another drug/device/biologic clinical trial during the study period; 15. Intracardiac thrombus, drug or alcohol addiction, unwillingness or inability to complete follow-up; 16. Severe renal insufficiency (eGFR \< 30); 17. Previous catheter ablation for atrial fibrillation; 18. Primary severe sick sinus syndrome.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Persistent atrial fibrillation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Persistent atrial fibrillation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ruijin Hostpial Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.